(ChemotherapyAdvisor) – A renal cancer vaccine improves overall survival, according to an international team of researchers who tested the vaccine. This conclusion is based on study entitled “Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival,” which was published online in Science on July 29.
In this published paper, the investigators reported the results of 2 clinical trials to evaluate IMA901 – “the first therapeutic vaccine for renal cell cancer (RCC) consisting of multiple tumor-associated peptides (TUMAPs) confirmed to be naturally presented in human cancer tissue.” To meet their aims, the investigators treated a total of 96 human leukocyte antigen A (HLA-A)*02-positive RCC patients with IMA901 in 2 consecutive studies.
The investigators reported the following results for these 2 clinical trials. “In the phase 1 study, the T-cell responses of the patients to multiple TUMAPs were associated with better disease control and lower numbers of pre-vaccine forkhead box P3 (FOXP3)-positive regulatory T (Treg) cells,” the investigators reported. “The randomized phase 2 trial showed that a single dose of cyclophosphamide reduced the number of Treg cells and confirmed that immune responses to multiple TUMAPs were associated with longer overall survival, which was predicted by 2 of 6 predefined populations of myeloid-derived suppressor cells. “Among over 300 serum biomarkers, we identified apolipoprotein A-I (APOA1) and chemokine (C-C motif) ligand 17 (CCL17) as being predictive for both immune response to IMA901 and overall survival,” they wrote.
The investigators concluded: “A randomized phase 3 study to determine the clinical benefit of treatment with IMA901 is ongoing.”